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Abstract
Histone acetylation plays a central role in gene regulation and is sensitive to the levels of metabolic intermediates.
However, predicting the impact of metabolic alterations on acetylation in pathological conditions is a significant
challenge. Here, we present a genome-scale network model that predicts the impact of nutritional environment and
genetic alterations on histone acetylation. It identifies cell types that are sensitive to histone deacetylase inhibitors
based on their metabolic state, and we validate metabolites that alter drug sensitivity. Our model provides a
mechanistic framework for predicting how metabolic perturbations contribute to epigenetic changes and sensitivity to
deacetylase inhibitors.
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Background
Protein acetylation is a highly conserved mechanism to
regulate many cellular processes including transcription
and metabolism. The substrate for acetylation, acetyl-
CoA, is a central metabolic intermediate at the crossroads
of anabolic and catabolic pathways [1]. Protein acetylation
is thus sensitive to the metabolic state of the cell [2]. Bio-
chemical assays in Saccharomyces cerevisiae and human
cell lines have shown that levels of acetyl-CoA directly
affect protein acetylation [3–5]. Hundreds of proteins, in-
cluding metabolic enzymes, are regulated by acetylation
[6, 7]. Acetylation can also influence gene expression
through post-translational modification of histones. Cells
rely on histone acetylation to increase chromatin accessi-
bility and influence gene expression [2, 8].
Given its pervasive regulatory role, altered acetylation
is believed to play a part in a variety of diseases
including cancer and metabolic disorders such as dia-
betes, obesity, dyslipidemia, and hypertension [5, 9–11].
Since metabolic alterations and dysregulation of protein
acetylation are important cancer hallmarks, understand-
ing the interplay between these processes can reveal
novel therapeutic targets against cancer. However, pre-
dicting the interplay between these two processes is
challenging due to acetyl-CoA’s pervasive role in metab-
olism, and due to the highly interconnected nature of
the metabolic network. No theoretical approach exists to
predict the impact of the change in cellular metabolism
on protein acetylation.
Creating a model of metabolism and protein acetyl-
ation can enable the prediction of the impact of nutrient
shifts or mutations in metabolic enzymes on the epige-
nome. This can shed light on metabolic and chromatin
dysregulation during tumorigenesis [12, 13]. Compounds
that disrupt acetylation machinery such as deacetylase
inhibitors are increasingly used for treating cancers and
metabolic and immune disorders [10]. Predicting the
interplay between metabolism and acetylation can iden-
tify cancer cells that are sensitive to deacetylase inhibi-
tors based on their metabolic state.
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To address this challenge, here we develop a computa-
tional model of metabolism and protein acetylation
using constraint-based modeling (CBM). CBM makes
use of metabolic network reconstructions that represent
the mechanistic relationships between genes, proteins,
and metabolites within a biological system. CBM has
been successfully used to predict the metabolic state of
various mammalian systems, including cancer cells and
stem cells [14–17]. We hypothesized that protein acetyl-
ation dynamics can be inferred from the metabolic net-
work topology and stoichiometry.
We demonstrate that our metabolic model can explain
known acetylation changes associated with nutrient excess
and starvation based on the availability of carbon units.
We then apply our acetylation model to predict and valid-
ate the impact of cellular metabolic state on sensitivity to
drugs that disrupt acetylation, specifically protein deacety-
lase inhibitors that are currently used in the clinic for anti-
cancer therapy. Our approach allowed us to predict the
variation in sensitivity between deacetylase inhibitors
based on their unique impact on cellular metabolism.
Results
Simulating the effect of the metabolic state on
acetylation
To simulate the influence of metabolism on acetylation, a
nuclear protein acetylation reaction (protein +
acetyl-CoA→ acetyl-protein + CoA) was incorporated
into the human metabolic network reconstruction by
Duarte et al., which contains 3747 reactions, 1496 ORFs,
2004 proteins, and 2766 metabolites [18]. A nuclear ATP
citrate lyase reaction and nuclear transport of citrate and
oxaloacetate were also included to enable synthesis of
acetyl-CoA in the nucleus based on recent biochemical
evidence [19]. Since acetyl-CoA and substrates for
acetyl-CoA synthesis can diffuse between the cytosol and
nucleus through the nuclear pore, the flux through the
protein acetylation reaction is representative of acetylation
changes in both cytosol and nuclear proteins.
To predict the impact of the cellular metabolic state
on acetylation, we subjected the metabolic model to dif-
ferent nutrient environments and simulated the impact
on acetylation (Figs. 1 and 2a). Specifically, the effect of
addition or removal of glucose, glutamine, essential
amino acids, and trace nutrients on acetylation was sim-
ulated using flux balance analysis (FBA) [20]. FBA iden-
tifies an optimal flux through the metabolic network
that maximizes an objective. In this case, we use the
commonly used FBA objective, the maximization of bio-
mass production. We also included the flux through the
protein acetylation reaction as a secondary FBA object-
ive, i.e., it has a relatively small optimization weight
compared to biomass. The underlying assumption is that
acetylation will consume a small fraction of the cellular
resources compared to biomass synthesis (Methods). To
support this assumption, we used data from total po-
tential acetylation sites in the human genome [13]
and experimental data on carbon flux tracing [21].
We mathematically estimated that diverting a small
fraction (< 5%) of the cytoplasmic flux of acetyl-CoA
would be sufficient to acetylate all the sites in a cell
in 24 h (Methods).
The metabolic model recapitulated known acetylation
changes occurring due to a shift in the metabolic state.
Switching to high or low glucose significantly affected
acetylation levels, which are known to change with glu-
cose flux [4, 19] (Fig. 2a). Bulk histone acetylation in yeast
cells has also been shown to be responsive to glucose
availability [3]. Addition of acetate, hypoxia, and starvation
of amino acids also increased acetylation flux, consistent
with experimental observations [19, 22–26]. To further
validate the impact of media components on acetylation
predicted by the model, we compared predictions with
data from recent biochemical studies [19, 27–29] (Fig. 2c).
Specifically, these studies measured the impact of addition
or removal of amino acids, glucose, acetate, minerals, and
vitamins on histone acetylation in cancer cell lines. Our
model correctly predicted the impact of 19 out of the 20
nutrient changes. These results suggest that acetylation
levels can be predicted based on the carbon flux and ener-
getic state of the cell.
Fig. 1 Overview of our systems approach to predict the impact of
metabolism on acetylation. Using a genome-scale metabolic model,
we first simulate the effect of different nutrient environments and
gene deletions on protein acetylation. We then simulate the impact
of the cellular metabolic state on vulnerability to compounds that
disrupt acetylation (protein deacetylase inhibitors). We subsequently
predict variation in susceptibility to these drugs between different
cell types depending on their metabolic state. Abbreviations—A, B
are metabolites and Enz1, Enz2, and Enz3 are metabolic enzymes
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The ability of the model to reproduce these diverse
observations provided new insights on the interaction
between acetylation and metabolism. Our analysis sug-
gests that bulk acetylation reflects excess carbon flux
that is not used for biomass synthesis. Hence, the model
predicted acetylation even in the absence of growth,
which was observed experimentally in conditions with a
carbon source but without a nitrogen source (i.e., deple-
tion of amino acids). In contrast, growth conditions
without excess carbon, such as those with amino acids
alone, did not display histone acetylation (Fig. 2c).
The inconsistent observation between the model and
experiment arose in a media condition lacking the car-
bon source—glucose. The model did not predict any
acetylation, while it was observed experimentally. Acetyl-
ation in this condition was only possible in the model if
there was an additional carbon source such as acetate or
fatty acids. A recent study has found significant levels of
acetate in DMEM media, which is usually not accounted
for in biochemical studies [30]. This acetate can replen-
ish cellular acetyl-CoA pools [30], and our modeling
suggests that this can potentially support histone acetyl-
ation. We then re-evaluated the model predictions after
including all nutrients that can be present in trace
amounts in serum—amino acids from uptake or degrad-
ation of serum proteins, trace amounts of fatty acids,
and acetate. These components are sufficient to support
acetylation in this condition that contained all major nu-
trients except glucose. However, the trace nutrients
were insufficient to promote acetylation if no major nu-
trients were present (Additional file 1: Figure S1). Thus,
this inconsistent prediction points to the potential role
of additional components in culture media that can im-
pact acetylation.
Fig. 2 Predicting the effect of genetic deletion and nutrient changes on bulk acetylation using FBA. a The bar chart depicts the impact of
reducing (purple bars) or increasing (orange bars) the level of metabolites in the culture media on acetylation flux (mmol/h per gram dry weight).
b The plot shows the effect of gene deletions on bulk acetylation. The impact of gene deletion on the biomass production was used as a
counter-screen to identify those genes that specifically impact protein acetylation. Gene deletions that exhibit at least 50% of the wild-type
biomass production rate are shown. The top 20 genes that preferentially affect acetylation over growth are highlighted as red markers and
displayed in the table. c Our model correctly predicted the impact of removing amino acids, pyruvate, glucose, acetate, fatty acids, vitamins, and
minerals from the media on acetylation. The plus/minus sign indicates the presence or absence of specific nutrients in the media. Conditions
predicted to have less than 5% of the wild-type acetylation flux by the model were assumed to be not supporting acetylation. Conditions
experimentally observed to support (+) or not support (−) acetylation are also denoted by a plus or minus sign. The condition with incorrect
prediction is shown in red. This incorrect prediction was resolved by accounting for trace nutrients in serum (Additional file 1: Figure S1)
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Metabolic modeling predicts bulk histone acetylation
levels in diverse cancer cell lines
Since FBA correctly identified the impact of distinct
metabolic conditions on acetylation levels, we next
tested if FBA can predict more nuanced differences in
the basal metabolic state and acetylation levels between
different cancer cell lines. We used bulk histone acetyl-
ation levels from LeRoy et al.’s study, which measured
acetylation levels using quantitative proteomics across a
panel of diverse cell lines representing lung, liver, colon,
and brain tumors [31].
To predict cell-type-specific changes in acetylation
levels due to their underlying metabolism, we inferred
their metabolic state from gene expression data [32].
Metabolic network models have been applied successfully
to predict metabolic behaviors of human tissues and can-
cer cells using transcriptomic data [33–36]. We obtained
gene expression data for the cell lines in LeRoy et al. study
from the Cancer Cell Line Encyclopedia (CCLE) project
[37] and integrated it with the human metabolic network
model using the iMAT approach [32] (Methods).
The transcriptional state of each cell line resulted in dis-
tinct metabolic states and acetylation levels. The predicted
acetylation flux of these 14 cell lines was compared to the
net acetylation levels measured using proteomics in these
cell lines. The acetylation levels predicted by the model
correlated significantly across all the cell lines with bulk
H3K9 acetylation levels, the major acetylation mark
known to be sensitive to metabolism (Pearson’s correl-
ation R = 0.6, p value = 0.022, FDR < 0.05, Fig. 3). However,
there was low non-significant correlation with other
acetylation marks (H3K27, R = 0.25, and H3K23, R = 0.35).
Given the small sample size of our dataset (14 cell lines),
the predictive power on other acetylation marks might be
discernable in a larger dataset in the future. Overall, our
analysis suggests that genome-scale modeling can predict
the impact of the cellular metabolic state on bulk histone
H3K9 acetylation.
Predicting metabolic enzymes that affect protein acetylation
We next performed gene deletion analysis to discover
metabolic genes that can impact acetylation. We systemat-
ically knocked out all 1487 metabolic genes in our model
and quantified the effect on protein acetylation (Fig. 2b).
This analysis identified 24 metabolic genes that reduced
acetylation flux by 1% or more relative to wild type (here-
after referred to as acetylation-impacting genes). This in-
cludes those known to affect acetylation such as enzyme
ATP citrate lyase (ACLY), TCA cycle genes such as IDH
and SDH, and the mitochondrial citrate transporter
SLC25A1 (Table 1). Cells lacking the ACLY displayed se-
verely reduced levels of bulk histone acetylation [24]. In
addition to the 24 acetylation-impacting genes, we also
identified 39 genes that increased acetylation when deleted
(hereafter referred to as acetylation-enhancing genes).
This set of 39 genes is involved in reactions that consume
acetyl-CoA. These include reactions in fatty acid synthesis,
one-carbon metabolism, and amino acid synthesis that
consume carbon units (Additional file 1: Table S1).
Our analysis uncovered several novel enzymes in
addition to those that have been previously reported to
impact acetylation. To assess the biological significance of
this prediction, we compared the 24 acetylation-impacting
metabolic genes with data from the protein acetylation
database [38], which catalogs all known acetylation targets
in humans. Proteomic studies have identified several
metabolic enzymes as targets of acetylation [6, 7, 39]. Pro-
teins encoded by 18 of the 24 acetylation-impacting genes
were themselves targets of protein acetylation. In addition,
a significant fraction of the enzymes predicted to affect
acetylation by the model were found to be direct targets
of Sirtuins, a major class of deacetylases. The fraction of
enzymes that were found to be acetylated and deacety-
lated among those predicted by the metabolic model
were significantly higher than would be expected by
chance (p value = 8 × 10− 15 for acetylation and p value
= 9 × 10− 6 for deacetylation respectively; Table 1). Intri-
guingly, none of the 39 acetylation-increasing genes
were targets of Sirtuins, suggesting that Sirtuins regu-
late reactions involved in production but not the con-
sumption of acetyl units.
To further corroborate our predictions of enzymes
that impact acetylation, physical interaction data from
literature were mined for associations between metabolic
enzymes and acetylation machinery. Proteins involved in
the same cellular process are more likely to physically
interact [40]. We hypothesized that the metabolic en-
zymes identified by our model to affect acetylation levels
will have strong physical interactions with acetylation or
deacetylated-related enzymes.
Using data from the Biogrid database [41], which con-
tains physical interaction data curated from literature, in-
teractions between metabolic and acetylation-related
enzymes in human cells were identified. Several metabolic
enzymes predicted by our model to influence acetylation
interacted physically with either a protein acetylase or dea-
cetylase enzyme (Additional file 1: Table S2, Table S3).
This overlap is significantly higher than expected by ran-
domly choosing a metabolic enzyme (p value = 0.01 and
0.002 for acetylation-impacting and acetylation-enhancing
enzymes respectively, hypergeometric test). Further, we
compared the extent of overlap with acetylases and
deacetylases separately. We observed a significant overlap
between acetylation-enhancing genes with protein deace-
tylases but not with acetylases (p value = 0.0004 and 0.07
respectively). In contrast, acetylation-impacting genes
have a significant number of interactions with both pro-
tein acetylases and deacetylases (p value = 0.003 and 0.005
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respectively). Thus, acetylases predominantly interact with
enzymes that lead to the synthesis of acetyl units. For ex-
ample, the acetylation-impacting enzyme ACLY had phys-
ical interactions with several acetylases. ACLY is known to
be transported to the nucleus to facilitate acetylation [42,
43]. The physical interaction suggests that the product of
the ACLY metabolic reaction (acetyl-CoA) can be directly
channeled as substrate for acetylases. We also found phys-
ical interactions between the TCA cycle enzymes citrate
synthase (CS) and succinate dehydrogenase (SDH) with
deacetylase enzymes HDAC5 and SIRT7 respectively.
Overall, our results suggest that enzymes identified by our
model to impact acetylation show strong functional asso-
ciation with protein acetylation pathways, thus corroborat-
ing our predictions.
Altering sensitivity of cancer cells to protein deacetylase
inhibitors by changing their metabolic state
Our analysis so far suggests that genome-scale modeling
can predict the impact of the metabolic state on global
protein acetylation. We next predicted the impact of the
cellular metabolic state on susceptibility to drugs that
disrupt cellular protein acetylation, specifically protein
deacetylase inhibitors. The human genome encodes 18
different lysine deacetylases (KDACs) that regulate nu-
merous biochemical pathways [7]. KDACs are consid-
ered attractive therapeutic targets for treating not just
cancers, but also viral infections, inflammation, neurode-
generative diseases, and metabolic disorders [10]. Four
deacetylase inhibitors (vorinostat, romidepsin, belino-
stat, panobinostat) are approved clinically for cancer
Fig. 3 Predicting the effect of the basal metabolic state on histone acetylation levels using FBA. a Schematic of the approach to infer the basal
metabolic state using transcriptomic data. The iMAT approach was used to integrate transcriptome data from a panel of cancer cell lines with the human
metabolic network model to infer cell-line-specific metabolic state and acetylation flux. b The scatter plot shows the predicted acetylation flux (mmol/
gDW cells/h) in each cell line and the bulk histone H3K9 acetylation levels from proteomics. The acetylation flux correlated significantly with the level of
bulk histone H3K9 acetylation in these cell lines. The acetylation flux in the high flux group of cell lines is constrained by the availability of carbon units
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treatment [44]. However, identifying tumors that are
sensitive to these drugs is a significant clinical chal-
lenge [45, 46].
Deacetylase enzymes catalyze the removal of acetyl-
ation marks from histones and other proteins. They are
sensitive to, and directly impact, the metabolic state of
the cell [47]. Deacetylase inhibitors block the deacetyla-
tion of proteins and are predicted to cause cell death by
increasing histone acetylation and triggering apoptosis
[45, 46, 48]. Hence, we hypothesized that conditions that
favor increased acetylation should enhance sensitivity to
these drugs.
Since genome-scale modeling allowed us to predict
metabolic conditions that increased protein acetylation,
we next used it to predict conditions that enhance sensi-
tivity to deacetylase inhibitors. Specifically, we explored
the use of metabolic network modeling to identify cell
types that are sensitive to KDAC inhibition based on their
metabolic and acetylation state. This can enable in silico
identification of tumors most sensitive to these drugs.
To validate our hypothesis, we experimentally mea-
sured the sensitivity of the ovarian cancer cell line
(HeLa) to vorinostat (also known as suberoylanilide
hydroxamic acid (SAHA)). Vorinostat was the first ap-
proved histone deacetylase inhibitor. HeLa cells were
cultured in 92 different metabolic conditions using Bio-
log phenotype microarrays and exposed to vorinostat or
control (DMSO). The culture conditions in the Biolog
arrays included a wide range of carbon sources that re-
sult in distinct patterns of metabolic activity in the cell
[49]. This broad range of metabolic activity allowed us to
assess the impact of the metabolic state of the cell on
vorinostat sensitivity.
The growth inhibition by vorinostat, quantified by area
under the growth curve (AUC) relative to control,
changed significantly with different nutrient conditions
Table 1 Functional significance of the 24 metabolic genes predicted by the model to impact acetylation
Gene Gene description 1. Acetylated? 2. Interacts with
acetylase?
3. Interacts with
deacetylase?
4. Sirtuin target?
AASS Aminoadipate-semialdehyde synthase X
ACLY ATP citrate lyase X X X
ACO2 Aconitase 2, mitochondrial X X X
ALDH1L1 Aldehyde dehydrogenase 1 family, member L1 X
CS Citrate synthase X X X
FAH Fumarylacetoacetate hydrolase (fumarylacetoacetase) X
FH Fumarate hydratase X X X
GOT1 Glutamic-oxaloacetic transaminase 1, soluble
(aspartate aminotransferase 1)
X
GSTZ1 Glutathione transferase zeta 1 X
HGD Homogentisate 1,2-dioxygenase X
HPD 4-Hydroxyphenylpyruvate dioxygenase
IDH2 Isocitrate dehydrogenase 2 (NADP+), mitochondrial X X X
PC Pyruvate carboxylase X X
OAT Ornithine aminotransferase X X X
RBKS Ribokinase
RPE Ribulose-5-phosphate-3-epimerase
SDHA Succinate dehydrogenase complex, subunit A, flavoprotein X X X X
SDHB Succinate dehydrogenase complex, subunit B, iron sulfur (Ip) X X X
SDHC Succinate dehydrogenase complex, subunit C X
SDHD Succinate dehydrogenase complex, subunit D X
SHMT1 Serine hydroxymethyltransferase 1 (soluble) X X
SLC25A1 Solute carrier family 25
(mitochondrial carrier; citrate transporter)
X X X
SUOX Sulfite oxidase X
TALDO1 Transaldolase 1 X X
Column 1 shows acetylation status based on protein acetylation database. Column 2 shows proteins that are found to physically interact with an acetylase.
Column 3 shows proteins that are found to physically interact with a deacetylase enzyme. Column 4 shows predicted targets of sirtuins, a major class of
deacetylases (X mark implies true)
Shen et al. Genome Biology           (2019) 20:49 Page 6 of 15
(Additional file 1: Table S4). Some growth conditions
such as succinate as a primary carbon source were pro-
tective of vorinostat treatment, while growth in fructose
or mannose enhanced sensitivity (Fig. 4). We then pre-
dicted the growth rate and acetylation flux in these con-
ditions using metabolic modeling and compared the
model predictions with sensitivity to vorinostat. Among
all the conditions tested, we compared those substrates
that supported growth in Biolog arrays and were part of
the metabolic model. The acetylation flux predicted in
each condition strongly correlated with vorinostat sensi-
tivity (R = − 0.66, p value = 0.0051, Fig. 4; Additional file 1:
Figure S2). Conditions that supported higher acetylation
flux had greater growth inhibition, consistent with our
hypothesis. In contrast, the predicted growth rate corre-
lated weakly with sensitivity (R = − 0.3, p value > 0.05).
While the predicted sensitivity showed high concord-
ance with experiments across most substrates, the model
incorrectly over-predicted acetylation flux and corre-
sponding sensitivity in conditions with maltose and gal-
actose as carbon sources; galactose is metabolized
differently despite similarity to glucose [50]. Intriguingly,
vorinostat enhanced the growth of cells under some
conditions. KDAC inhibitors are known to reduce glu-
cose metabolism and increase mitochondrial oxidative
metabolism [51]. This metabolic impact may be benefi-
cial in conditions that lack glucose or other fermentable
sugars. We observed a strong correlation between the
Fig. 4 Changing the metabolic state predictably alters sensitivity to the deacetylase inhibitor—vorinostat. a Schematic of the phenotype
microarray analysis. HeLa cells were cultured in different metabolic conditions and exposed to vorinostat or control (DMSO). The metabolic state
and acetylation flux in each condition were determined using FBA. b The acetylation flux (mmol/gDW cells/h) correlated significantly with the
extent of growth inhibition by vorinostat. The scatter plot shows the predicted acetylation flux in each metabolic condition and the ratio of the
area under the growth curve (AUC) for vorinostat treatment relative to control. Conditions with lower ratio (< 1) were more sensitive to vorinostat
and showed higher acetylation flux. Average of four replicates shown
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extent of growth enhancement and acetylation flux pre-
dicted in those conditions (Additional file 1: Figure S2).
Hence, KDAC inhibitors may enhance growth in condi-
tions with low acetylation while inhibiting growth in
conditions with high acetylation flux. This dependence
on the cellular metabolic state may explain the
growth-promoting effect of KDAC inhibitor treatment
on stem cells and neurons [52, 53].
Predicting cellular sensitivity to protein deacetylase
inhibitors using the metabolic state
Since distinct metabolic conditions showed differences
in sensitivity to vorinostat, we next tested if our model
can predict more nuanced differences in metabolic activ-
ity between different cancer cell lines and their corre-
sponding impact on sensitivity to KDAC inhibitors.
Large-scale therapeutic screening data from Seashore-
Ludlow et al. was used to identify variation in sensitivity
to KDAC inhibitors among a panel of 860 cancer cell
lines encompassing various tissue and tumor types [54].
The transcriptomic state of these cell lines has been
characterized using microarrays as part of the Cancer
Cell Line Encyclopedia (CCLE) project [37].
We integrated gene expression data for the CCLE cell
lines along with their growth media composition with
the genome-scale human metabolic network model to
infer their metabolic state using the iMAT approach
(Methods). The sensitivity of these cell lines to vorino-
stat was compared to the net acetylation flux predicted
by the model in each of these cell lines. Overall, the net
acetylation flux in these cell lines was bimodal in nature
with a very low and high flux group (Fig. 5b;
Additional file 1: Figure S3). The high flux group showed
higher expression levels of reactions associated with
acetyl-CoA synthesis and fatty acid metabolism such as
acetyl-CoA synthetase and propionyl-CoA carboxylase
(Additional file 1: Table S5).
We compared the sensitivity of the cell lines with high
acetylation flux state with those with low acetylation
flux. Cell lines with high acetylation flux were found to
be significantly more sensitive to vorinostat treatment
than those with low acetylation flux (Fig. 5c; p value =
4 × 10− 6, t-test). This is consistent with the observation
across metabolic conditions using Biolog phenotype ar-
rays. The low throughput Biolog assays revealed a strong
quantitative relationship with the model predictions.
However, these were observed with a single cell line. In
contrast, the high-throughput drug-screening assays
from Seashore-Ludlow et al. involve hundreds of cell
lines. Our results across this large dataset suggest that
this is a statistically robust phenomenon.
To assess the generality of this observation to other
KDAC inhibitors, we compared the pattern of sensitivity
between high and low acetylation flux cell lines using
data from three other clinically used KDAC inhibitors
that were part of the Seashore-Ludlow et al. dataset—
panobinostat, entinostat, and belinostat. Entinostat is
currently in phase III clinical trials, and the other two
drugs are FDA approved. All these drugs were signifi-
cantly more sensitive to high acetylation flux state cell
lines (p value < 10− 6, t-test; Fig. 5c, Additional file 1:
Figure S3). Overall, these results suggest that the meta-
bolic and acetylation state is predictive of sensitivity to
KDAC inhibitors.
Finally, to assess the specificity of the acetylation flux
metric in predicting sensitivity to KDAC inhibitors, we
compared the differential sensitivity of all 481 com-
pounds that were part of the Seashore-Ludlow et al.
study between the high and low acetylation flux cell
lines. KDAC inhibitors were significantly more strongly
selective between the two groups than other drug clas-
ses (p value = 0.003, t-test; Additional file 1: Figure S4).
This trend applies to both experimental and clinically
used KDAC inhibitors (Additional file 1: Figure S4).
Thus, the observed trend is not due to an indirect cor-
relation with other cellular processes such as the
growth rate. Indeed, we observed a stronger trend using
the Seashore-Ludlow et al. data after correcting for
doubling time of each cell type (p value = 7 × 10− 9,
Additional file 1: Figure S5).
Predicting variability between protein deacetylase
inhibitors
So far, we have predicted the impact of the cellular
metabolic state on sensitivity to protein deacetylase in-
hibitors. We next incorporated the direct impact of
these drugs on cellular metabolism. Vorinostat treat-
ment has been previously shown to reduce glucose and
fatty acid metabolism in myeloma cell lines [51]. Incorp-
orating the impact of these drugs on metabolism would
allow us to predict differences in sensitivity resulting
from both basal metabolic state and the unique impact
of each KDAC inhibitor. KDAC inhibitors display vari-
ability in their sensitivity to different cell types [53].
KDAC inhibitors block distinct histone deacetylases
resulting in transcriptomic changes that influence the
levels of metabolic enzymes [48, 53].
To model the unique effect of each drug, we inter-
preted the pattern of differential gene expression from
cells exposed to these drugs with metabolic network
models. We used data measured in one representative
cell line and used it to predict the metabolic impact of
each KDAC inhibitor on all CCLE cell lines. We ana-
lyzed transcriptomic signatures of four different KDAC
inhibitors (vorinostat, panobinostat, entinostat, and beli-
nostat) before and after treatment from UKN1 cells [55].
Several metabolic genes were uniquely differentially
expressed in response to each KDAC inhibitor, which
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may lead to variation in sensitivity (Additional file 1:
Table S6). This list of downregulated and upregulated
genes was overlaid onto all the CCLE cell line metabolic
models to predict variation in drug sensitivities among
the CCLE cell lines. The net acetylation flux due to both
basal transcriptomic state and drug-induced transcrip-
tomic changes were determined for all cell lines for the
four KDAC inhibitors using the iMAT approach.
We compared the extent of acetylation flux change
caused by each drug in a cell line to the sensitivity of
each of these drugs. Cell lines showing higher acetyl-
ation flux reduction for a drug relative to others dis-
played significantly greater growth inhibition to that
drug, with an average of 25.3% difference in growth
(equivalent to 2.6 AUC units, p value = 10− 62, t-test,
Fig. 6). Overall, cell lines with high basal acetylation
flux are more sensitive to all KDAC inhibitors; fur-
ther, the extent of acetylation flux reduction after
drug treatment correlates with sensitivity to the
corresponding KDAC inhibitor. Thus, combining the
impact of basal metabolic state and the impact of
KDAC-induced differential enzyme expression can
predict both sensitivity and variability between KDAC
inhibitors. In sum, our study provides a framework for
predicting the potency of KDAC inhibitors from baseline
(pre-treatment) transcriptomic profiles. Additional file 1:
Fig. 5 Predicting sensitivity to deacetylase inhibitors by inferring basal metabolic network state. a Schematic overview of the analysis comparing the
sensitivity of cell lines from CCLE to deacetylase inhibitors and their corresponding metabolic state. b The histogram shows the distribution of
predicted acetylation flux (mmol/gDW cells/h) among the CCLE cell lines. The data revealed two groups of cell lines—cell lines predicted to have no
or very low acetylation flux (flux < 0.05) and a high flux group (flux > 0.05). c KDAC inhibitors, vorinostat, panobinostat, belinostat, and entinostat, were
significantly more sensitive against the high flux group than the low flux group of cell lines (p value < 10− 5, t-test; Additional file 1: Figure S3). The bar
graphs depict the area under the growth curve (AUC) of CCLE cell lines after treatment with the drugs, with lower AUC implying greater growth
inhibition. The results are robust to the cut-offs for high and low acetylation flux group (Additional file 1: Figure S3)
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Figure S6 summarizes the steps for applying our approach
for a new cell line or tumor sample.
Discussion
In this study, we built a genome-scale biochemical
model to predict the impact of cellular metabolic state
and availability of nutrients on acetylation. A key
observation from our study is that histone acetylation
dynamics reflects the flux of excess carbon that is not
used for biomass synthesis (overflow metabolism). Over-
flow metabolism has also been proposed to drive acetyl-
ation in prokaryotes [56, 57]. Conditions that lack amino
acids or oxygen can increase acetylation as there is ex-
cess carbon available for acetylation from glucose.
Fig. 6 Metabolic rewiring by KDAC inhibitors predicts variation in sensitivity between these inhibitors among cancer cell lines. a Overview of the
analysis comparing the sensitivity of CCLE cell lines to four KDAC inhibitors—vorinostat, panobinostat, belinostat, and entinostat. The acetylation
flux in each cell line corresponding to each drug treatment was determined by FBA by accounting for both the basal transcriptomic profiles of
each cell line and the metabolic impact of these drugs. Cell line-drug combinations were grouped into two classes—the first group of cell line-
drug pairs did not show any significant difference in acetylation flux compared to the other drugs, while the second class showed large
differences. b The histogram and box plots show the distribution of normalized sensitivity scores of the four drugs among the two cell line
groups. The experimental sensitivity data was median normalized so that a score of 0 implies that there was no difference in sensitivity between
the drugs while a negative score implies greater sensitivity for a drug relative to other three drugs. The normalized sensitivity scores were
significantly lower for the group that showed large difference in acetylation flux between the drugs compared to the group that showed no
acetylation flux difference (p value = 2 × 10− 62, t-test)
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Strikingly, we observed acetylation even in certain nutri-
ent starvation conditions that do not support growth,
which is also observed experimentally (Fig. 2c).
Our analysis also identified known and novel meta-
bolic enzymes that can impact acetylation. These predic-
tions were supported by numerous physical interactions
between the acetylation-impacting metabolic enzymes
predicted by our model with proteins in the acetylation
machinery. This suggests that the activity of these meta-
bolic enzymes can impact protein acetylation and are in
turn regulated by protein acetylation. This reciprocal
regulation to maintain homeostasis has also been ob-
served between metabolic pathways and signaling path-
ways [58–60] .
Since acetylation plays a central role in signaling and
chromatin regulation, mutations in the acetylation-
impacting metabolic genes can significantly affect cellu-
lar homeostasis. The acetylation-impacting genes, IDH2,
SDHA/B/C, and FH, are annotated as being frequently
mutated in cancers in the COSMIC database [61]. Aber-
rant expression of these genes may also lead to altered
acetylation in tumors. The genes ACLY, CS, RPE, and
IDH2 were found to be among the top 10% of the genes
that were frequently overexpressed across 19 cancer
types from a meta-analysis study of 1981 tumors (FDR p
value < 0.05) [62]. These genes predicted by our model
are potential drug targets for disorders with dysregulated
epigenome.
We then demonstrated that our model can predict the
impact of the metabolic state on sensitivity to deacety-
lase inhibitors. We hypothesized that conditions that
favor increased acetylation should enhance sensitivity to
these drugs, which cause cell death by blocking deacety-
lation. Consistent with this hypothesis, we were able to
predict and validate both metabolic conditions and cell
types that show increased sensitivity to these drugs. Our
experimental screen across diverse metabolic conditions
revealed that sensitivity to vorinostat changed signifi-
cantly with the metabolic state. Notably, our biochemical
model accurately predicted the sensitivity to vorinostat
by predicting the acetylation flux in diverse nutrient
conditions. Nutrients that were modeled in this study
such as glucose, acetate, amino acids, and lactate are also
metabolized by tumors in vivo [63, 64]. While glucose is
the common carbon source, some tumors also use lac-
tate [64]. Our analysis suggests that while glucose condi-
tion increases sensitivity, growth in lactate may offer
protection against vorinostat. Hence, this drug may be
effective only against some tumor types. This is poten-
tially relevant for targeting cancers with distinct meta-
bolic states [65]. While the tumor microenvironment is
complex and dynamic, our ability to predict the impact
of drug efficacy in simple defined environments is the
first step towards addressing the in vivo complexity. Our
study paves the way for dynamic models that can simu-
late the impact of changing the metabolic conditions.
Analysis of KDAC inhibitor sensitivity across 860 can-
cer cell lines revealed that differences in basal metabolic
state among cells can lead to variation in sensitivity.
Using metabolic modeling, we were able to group cell
lines based on their acetylation state and predict those
that show increased sensitivity to deacetylase inhibition.
Identifying tumors that are sensitive to specific KDAC
inhibitors is a significant clinical challenge [46]. Our ap-
proach can help predict efficacy of deacetylase inhibitors
against different cancer types using transcriptomic data.
Transcriptomic profiling is increasingly done for tumors
for treatment stratification and prognosis [66]. A very
small tissue sample is needed for transcriptomics
compared to the requirements for cell culture and
drug screening.
Furthermore, unique differences in the transcriptomic
pattern induced by each KDAC inhibitor correlate with
variation in sensitivity between these inhibitors. By ana-
lyzing sensitivity to four clinically used KDAC inhibitors
across all CCLE cell lines, we found that cell lines that
showed higher acetylation flux reduction after treatment
with a KDAC inhibitor relative to others were more sen-
sitive to the corresponding drug. Our approach comple-
ments machine-learning and high-throughput screening
approaches [67] by providing a rational mechanistic
strategy to predict and tune sensitivity of KDAC inhibi-
tors based on acetylation flux. Genome-scale modeling
has been shown to accurately predict the metabolic state
of cancer cells from transcriptomic data. Future analysis
using proteomics and metabolomics data could lead to
tumor stratification with greater accuracy.
While we have focused on the impact of metabol-
ism and nutrition on acetylation in this study, the ac-
tivity of acetylases and metabolic enzymes can also be
regulated by signaling pathways which can subse-
quently impact bulk acetylation levels [7]. Further,
while our model predicts bulk acetylation levels, it
does not provide insights on acetylation changes in
specific protein sites. In future, knowledge of specific
targets, binding affinity, and expression levels of
acetylation and deacetylation enzymes can enable pre-
diction of acetylation dynamics at specific sites in the
proteome. Similarly, incorporating the role of redox
factors, FADH and NADH, that can influence activity
of deacetylases can potentially resolve inconsistencies
observed in nutrient conditions such as galactose
media that impact redox state [68]. Similar to acetyl-
ation, which is sensitive to the flux of acetyl-CoA, re-
cent studies have revealed that histone methylation is
sensitive to the flux of the substrate S-Adenosyl Me-
thionine (SAM) [17, 69]. Our study can pave the way
for modeling other histone modifications like
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acylation, succinylation, and methylation that also de-
pend on metabolic intermediates.
Conclusion
Histone acetylation links gene regulation with metabol-
ism, and aberrant acetylation is associated with cancers
and metabolic disorders. Here we developed a
genome-scale biochemical network model to predict the
impact of metabolism on acetylation. Our model re-
vealed that histone acetylation levels change predictably
depending on cellular carbon and nutrient availability.
We identified several novel metabolic genes that can im-
pact acetylation when deleted. Our approach provided
two key insights related to cellular metabolism and sen-
sitivity to deacetylase inhibition. Firstly, our experimen-
tal screen across diverse metabolic conditions and
analysis across 860 cancer cell lines revealed that sensi-
tivity to deacetylase inhibitors can be predicted from the
cellular metabolic state. Secondly, unique rewiring of
metabolic pathways induced by each KDAC inhibitor
correlates with variability between these inhibitors. This
is potentially relevant for tumor treatment stratification
based on the metabolic state. Overall, our study demon-
strates the strong and predictable interconnection be-
tween metabolism and acetylation.
Methods
Flux balance analysis (FBA)
In FBA, an optimal metabolic flux state is determined
that maximizes an objective (usually the biomass). We
used the biomass composition from Shlomi et al. [70]
for the growth objective function. The biomass objective
function represents the steady-state consumption of 42
essential metabolites, such as nucleotides, amino acids,
and lipids required for cellular proliferation. In addition
to maximizing the objective, the following constraints
are satisfied—(1) the system is at steady state with mass
balanced for all species (i.e., no accumulation or deple-
tion of any intracellular metabolites in the network) and
(2) the specified upper and lower bounds for each reac-
tion in the network are not violated. FBA was used for
simulating the impact of gene deletions and metabolic
environment on protein acetylation. A total of 50 nutri-
ents commonly present in rich media culture were used
as starting points for nutrient addition in excess and nu-
trient removal.
FBA was performed in different nutrient environments
with the protein acetylation reaction as the secondary
objective (Optimization objective: maximize Biomass_-
reaction + epsilon × acetylation_reaction). Acetylation
flux is optimized after biomass synthesis is maximized.
We used a parameter (“epsilon”) to incorporate the rela-
tive weights for optimizing biomass flux relative to
acetylation. Changing the value of epsilon (i.e., relative
weights) over a 10,000-fold range from 0.01 to 10− 6 does
not influence the value of acetylation flux and the accur-
acy of our approach (Additional file 1: Figure S7, Add-
itional file 1: Table S7). The two objectives optimized
here can be conflicting or potentially independent de-
pending on nutrient availability. Since acetylation flux is
a secondary objective for our optimization, any value of
epsilon that is relatively small compared to biomass
function would lead to the same value of acetylation
flux. The mathematical approach used here with separ-
ate weights for different objectives is the most common
way of solving such multi-objective problems [71]. This
approach is scalable to any number of objectives.
Total carbon flux necessary for acetylation compared to
other biosynthetic processes
Using data from total potential acetylation sites in the
human genome [13], we find that diverting a small frac-
tion of the cytoplasmic flux of acetyl-CoA would be suf-
ficient to acetylate all the sites in a cell. The observed
flux through cytosolic acetyl-CoA synthesis reaction in
human iBMK cells is 2 nmol/h/μlcells [21], which is
equivalent to 109 molecules per hour in each cell. As-
suming a total of 109 acetylation sites in a mammalian
cell [13], redirecting 1/24th of the cytosolic acetyl-CoA
production flux towards the nucleus in a period of 24 h
can be sufficient to saturate all the histone acetylation
sites, assuming a relatively low rate of deacetylation [63].
The mitochondrial carbon flux towards acetyl-CoA is
10-fold higher than cytosolic flux [21]. This suggests that
redirection of carbon flux towards acetylation will not
significantly impact biomass synthesis.
Transcriptomic data integration
To integrate transcriptomic data with the metabolic net-
work model, we used a linear version of the iMAT ap-
proach [32] implemented in the PROM algorithm [72].
In the iMAT approach, the number of active reactions
associated with genes that are upregulated or highly
expressed is maximized, while flux through reactions as-
sociated with downregulated reactions are minimized.
The linear optimization version of the iMAT approach
allows for continuous restriction of fluxes instead of set-
ting reactions to be completely on or off [72]. The
constraints are flexible, i.e., they allow for violation of in-
dividual constraints in order to maximize the overall
consistency with the data. These inconsistencies may
represent sites of regulation by other regulatory mecha-
nisms [32]. We used this approach to infer a
cell-type-specific metabolic state using transcriptomic
data for CCLE cell lines and to incorporate transcrip-
tomic evidence from KDAC inhibitor profiling data. The
optimization problem was solved using the Gurobi
mathematical programming solver. The entire series of
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steps for predicting acetylation flux from transcriptomic
data is outlined in Additional file 1: Figure S8 and
Additional file 1: Figure S9.
To assess the robustness of our results to the method
of transcriptome integration, we repeated all our ana-
lyses with an alternative approach for transcriptomic
data integration called GIMME [73]. This approach dif-
fers from the iMAT approach in that it assumes a direct
linear association between extent of downregulation of a
gene’s expression and the downregulation of flux through
the corresponding enzyme encoded by it. We found that
our results from this approach are consistent with our re-
sults using iMAT (Additional file 1: Table S8).
Small molecule therapeutic screening data
Area under the growth curve (AUC) values for the small
molecule therapeutic screening data for 481 compounds
against 860 cell lines were obtained from Seashore-
Ludlow et al. along with media used for each of the 860
cell lines. The media composition and transcriptomic
data for these cell lines from CCLE was used to infer the
metabolic network state for these cell lines as described
above. In order to estimate the impact of the cellular
doubling rate on drug sensitivity, we also used data from
Hafner et al. that controls for this effect [74]. The
growth-controlled efficacy metric was found to be super-
ior to existing metrics for assessing the efficacy of drugs
in dividing cells. Cell lines with missing growth inhib-
ition values for the KDAC inhibitors were removed from
the statistical analysis.
Biolog phenotype microarray (PM) measurement
The phenotype microarray (PM) plates from Biolog Inc.
(Hayward, CA, USA) contain diverse energy sources to
profile the metabolic capabilities of a cell. Each well in a
PM plate contains a single chemical as the sole energy
source and production of NADH per well is monitored
using a colorimetric redox dye chemistry. As the cells
metabolize the energy source, tetrazolium dye in the
media is reduced, producing a purple color according to
the amount of NADH generated. The PM-M1 plate used
in this study contains 92 different carbon energy sources
along with negative control wells.
Biolog PM assays were performed as described in Boc-
cuto et al. [75]. Viable cells were counted utilizing a
TC20™ Automated Cell Counter. PM-M1 plates were in-
cubated with 20,000 viable cells per well in a volume of
50 μL. The cells were incubated at 37 °C in 5% CO2,
using the modified Biolog IF-M1 medium [75]. HeLa
cells were exposed to vorinostat (2 μM) or DMSO (con-
trol) at the time they were added to the Biolog PM
plates, for a 72-h exposure. The experiment was con-
ducted in four replicates using the PM-M1 plate. During
the final 24 h of exposure, the optical density of each
well was measured every 15 min. The optical readings
were normalized using quadruplicate readings from an
empty plate (plates run with no cells, just media and
dye). The normalized optical density readings were used
for statistical analysis.
To control for the impact of slow or no growth, we
used only those conditions that supported any growth
above negative control (Background). Using various
thresholds for growth did not impact the strong correl-
ation between the predicted acetylation flux and growth
inhibition (Additional file 1: Figure S2).
Statistical analysis
The significance of overlap between gene lists was esti-
mated using the hypergeometric test in MATLAB. Bio-
log data analysis was performed in R.
Additional file
Additional file 1: File contains Supplementary figures 1-9 and Supple-
mentary tables 1-8. (PDF 1.8 MB)
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